How should a patient with decompensated chronic liver disease presenting with disseminated and miliary tuberculosis in shock be managed?

Management of Decompensated Chronic Liver Disease with Disseminated/Miliary TB in Shock

Immediately initiate hemodynamic resuscitation with norepinephrine as first-line vasopressor, balanced crystalloids or albumin for volume, and start empiric anti-TB therapy with a modified non-hepatotoxic regimen (ethambutol + fluoroquinolone + streptomycin) while simultaneously treating the shock, as disseminated TB presenting with septic shock in cirrhotic patients carries extremely high mortality and requires urgent dual management of both conditions. 1, 2, 3

Immediate Hemodynamic Stabilization

Shock Management

• Target mean arterial pressure (MAP) ≥ 65 mm Hg with ongoing assessment of end-organ perfusion using invasive arterial and central venous monitoring. 1
• Norepinephrine is the first-line vasopressor; add vasopressin as second-line agent when escalating norepinephrine doses are required. 1
• Use balanced crystalloids (lactated Ringer's) or albumin for volume resuscitation with judicious fluid strategy guided by bedside echocardiography to assess volume status and cardiac function. 1
• Screen for relative adrenal insufficiency or provide empiric hydrocortisone 50 mg IV every 6 hours (or 200-mg continuous infusion) for refractory shock requiring high-dose vasopressors, as adrenal insufficiency occurs in 49% of decompensated cirrhosis patients and is associated with 26% vs. 10% mortality. 1

Critical Pitfall

Do not delay anti-TB therapy while awaiting microbiological confirmation in patients with suspected disseminated TB and septic shock—mortality is extremely high and prompt empiric treatment is life-saving. 3

Anti-TB Therapy Selection Based on Liver Dysfunction Severity

For Decompensated Cirrhosis (Child-Pugh ≥ 8) in Shock

Use a completely non-hepatotoxic regimen from the outset given the patient is already in shock with decompensated liver disease and cannot tolerate any additional hepatic insult. 2, 4, 5

Recommended initial regimen:

• Ethambutol (standard dosing)
• Fluoroquinolone (levofloxacin 750–1000 mg daily or moxifloxacin 400 mg daily)
• Streptomycin (injectable agent, 15 mg/kg IM/IV daily or 3 times weekly)
• Cycloserine (if tolerated, 500–750 mg daily in divided doses)
• Duration: 18–24 months 2, 4

Critical Contraindication

Avoid aminoglycosides (streptomycin) if there is evidence of severe coagulopathy (elevated INR) or thrombocytopenia due to markedly increased bleeding risk in advanced liver disease. 2 In this scenario, substitute with cycloserine or a second-line injectable agent under specialist guidance.

Alternative Approach for Child-Pugh 8–10 (if shock resolves rapidly)

If hemodynamic stability is achieved quickly and liver function shows no further deterioration, consider one hepatotoxic drug (rifampicin preferred over isoniazid for superior efficacy) + ethambutol + fluoroquinolone for 12–18 months. 2, 4 However, given the patient is presenting in shock, the safer approach is to avoid all hepatotoxic agents initially.

Diagnostic Confirmation & Monitoring

Microbiological Sampling

• Obtain sputum, blood cultures, ascitic fluid (if present), urine, and consider bone marrow or gastric aspirate for acid-fast bacilli smear, culture, and molecular testing (GeneXpert MTB/RIF). 6, 3
• Disseminated TB in cirrhotic patients is frequently misdiagnosed as spontaneous bacterial peritonitis or Gram-negative sepsis; maintain high clinical suspicion. 6

Baseline Liver Assessment

• Measure ALT, AST, bilirubin, alkaline phosphatase, albumin, and INR before initiating therapy. 2
• INR monitoring is essential in severe hepatic impairment to detect worsening coagulopathy. 2
• Test for hepatitis B surface antigen, anti-HCV antibodies, and HBV DNA if HBsAg-positive, as active viral replication (HBV DNA > 2000 IU/mL) increases risk of fatal drug-induced liver injury (adjusted HR 4.40). 2

Ongoing Monitoring During Treatment

• Weekly liver function tests for the first 2 weeks, then every 2 weeks for 2 months, then monthly in all patients with chronic liver disease receiving anti-TB therapy. 2
• Daily clinical assessment for hepatitis symptoms (nausea, vomiting, abdominal pain, jaundice, dark urine, fever). 2
• Monitor renal function weekly and perform baseline audiometry before streptomycin, with ongoing ototoxicity surveillance. 2

Management of Hepatotoxicity if It Develops

Immediate Discontinuation Thresholds

Stop all hepatotoxic drugs immediately if:

• AST/ALT ≥ 5 × ULN in asymptomatic patients, or
• AST/ALT ≥ 3 × ULN with any hepatitis symptoms, or
• Any rise in bilirubin above baseline, or
• Development of hepatic encephalopathy 2

Bridging Therapy During Hepatic Recovery

• Continue streptomycin + ethambutol (or ethambutol + fluoroquinolone if aminoglycosides contraindicated) as inpatient bridging until liver enzymes normalize. 2
• Initiate lactulose (titrate to 2–3 bowel movements daily) immediately if hepatic encephalopathy develops; add rifaximin 550 mg twice daily for severe or refractory encephalopathy. 2
• Identify and treat precipitating factors: infection, GI bleeding, constipation, dehydration, electrolyte disturbances. 2

Sequential Drug Re-introduction (only if liver function normalizes and TB regimen must be optimized)

Re-introduce drugs only after ALT/AST < 2 × ULN, bilirubin returned to baseline, and patient asymptomatic, using the following protocol with daily liver function testing: 2

Step	Drug	Starting Dose	Escalation	Target Dose
1	Isoniazid	50 mg once daily	→ 300 mg after 2–3 days if tolerated; maintain 2–3 days	300 mg daily
2	Rifampicin	75 mg once daily	→ 300 mg after 2–3 days; then → 450 mg (<50 kg) or 600 mg (≥50 kg) after another 2–3 days	450–600 mg daily
3	Pyrazinamide	250 mg once daily	→ 1.0 g after 2–3 days; then → 1.5 g (<50 kg) or 2.0 g (≥50 kg) after another 2–3 days	1.5–2.0 g daily

Critical caveat: In a patient who presented with decompensated cirrhosis in shock, re-introduction of hepatotoxic drugs carries prohibitive risk; maintain the non-hepatotoxic regimen for the full 18–24 months. 2, 4

Respiratory Support & Complications

Acute Respiratory Distress Syndrome (ARDS)

• Patients with acute-on-chronic liver failure (ACLF) are at high risk of acute lung injury and ARDS from miliary TB. 1
• Perform bedside echocardiography to differentiate hydrostatic (diastolic dysfunction, volume overload) from non-hydrostatic pulmonary edema (ARDS, pneumonia). 1
• Evaluate for hepatic hydrothorax, portopulmonary hypertension, and hepatopulmonary syndrome, which can worsen respiratory failure. 1

Nutritional Support

• Provide 35–40 kcal/kg/day energy and 1.2–1.5 g/kg/day protein to prevent sarcopenia and support hepatic recovery. 2
• Do not restrict protein even in hepatic encephalopathy, as restriction worsens catabolism and muscle loss. 2
• Offer small frequent meals (4–6 times daily including night snack) to improve long-term prognosis. 2

Prognosis & Specialist Consultation

• Mortality is extremely high in disseminated TB presenting with septic shock in cirrhotic patients; case reports document death within 1 month despite treatment. 6
• Immediate hepatology and infectious disease consultation is mandatory for Child-Pugh ≥ 8 or suspected drug-induced liver failure. 2
• Consider liver transplantation evaluation for severe encephalopathy unresponsive to medical therapy, as acute liver failure with encephalopathy has poor prognosis. 2

Key Pitfalls to Avoid

• Never continue hepatotoxic anti-TB drugs after meeting discontinuation thresholds—this dramatically increases acute liver failure risk. 2
• Never delay empiric anti-TB therapy in suspected disseminated TB with shock awaiting culture confirmation—prompt treatment is life-saving. 3
• Never re-introduce pyrazinamide if it caused severe hepatotoxicity with bilirubin elevation—it must be permanently excluded. 2
• Never restrict protein intake in hepatic encephalopathy—this worsens outcomes. 2